4
Changes in Ownership
ArriVent BioPharma, Inc. Filed Acc 0001104659-24-008799
Director bought 444,444 shares at $18.00 ($7,999,992)
- Director acquired 2,582,884 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC Director | 2024-01-30 | Conversion | +821,827 | 821,827 | I | ||
| ORBIMED ADVISORS LLC Director | 2024-01-30 | Conversion | +821,827 | 821,827 | I | ||
| ORBIMED ADVISORS LLC Director | 2024-01-30 | Conversion | +469,615 | 1,291,442 | I | ||
| ORBIMED ADVISORS LLC Director | 2024-01-30 | Conversion | +469,615 | 1,291,442 | I | ||
| ORBIMED ADVISORS LLC Director | 2024-01-30 | Purchase | +222,222 | $18.00 | $3,999,996 | 1,513,664 | I |
| ORBIMED ADVISORS LLC Director | 2024-01-30 | Purchase | +222,222 | $18.00 | $3,999,996 | 1,513,664 | I |
| Derivatives | |||||||
| ORBIMED ADVISORS LLC Director | 2024-01-30 | Conversion · Series A Preferred Stock | −821,827 | 0 | I | ||
| ORBIMED ADVISORS LLC Director | 2024-01-30 | Conversion · Series A Preferred Stock | −821,827 | 0 | I | ||
| ORBIMED ADVISORS LLC Director | 2024-01-30 | Conversion · Series B Preferred Stock | −469,615 | 0 | I | ||
| ORBIMED ADVISORS LLC Director | 2024-01-30 | Conversion · Series B Preferred Stock | −469,615 | 0 | I | ||
| Open-market purchases · 444,444 sh · avg $18.00 · $7,999,992 | |||||||
Loading xslF345X05/tm244611-1_4seq1.xml…